Announcement of Daiichi Sankyo Science & Technology Day 2025

Key Announcements

At Science & Technology Day 2025, Daiichi Sankyo announced the latest advancements in DXd ADC technology and growth strategies for its oncology business. Enhertu® has been used by 194,000 patients worldwide, with global product sales reaching 552.8 billion yen in FY2024, demonstrating a 40% year-over-year growth. Datroway® achieved global product sales of 10.4 billion yen in Q2 FY2025, marking a 95.9% increase over the previous quarter. Through multiple new indication approvals and clinical trial progress, the company plans to obtain numerous indications for four ADCs by 2030, contributing to approximately six times more patients. On the manufacturing front, a global supply system has been established utilizing both in-house factories and CMOs, aiming for stable supply.

Impact on Investors

Daiichi Sankyo’s DXd ADC technology is highly regarded globally, with remarkable sales growth of Enhertu® and Datroway®. Future expansion of the oncology business is expected through the acquisition of new indications and successful clinical trials. Strengthening the global supply system and cultivating biopharmaceutical talent prepares the company to meet increasing demand. These initiatives are expected to support sustainable growth and contribute to medium- to long-term value creation for investors.